Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

How Has the Vutrisiran Market Growth Performance Trended Historically, And What Lies Ahead?

In recent times, there has been substantial expansion in the vutrisiran market, escalating from $0.60 billion in 2024 to an estimated $0.68 billion in 2025, with a compound annual growth rate (CAGR) of 12.8%. The noticeable upturn during this historical period can be credited to the heightened awareness concerning hereditary transthyretin amyloidosis, an increase in clinical trials, a rise in healthcare expenditure, growing preference among patients for non-invasive administration techniques, and an upswing in genetic disorders.

Expectations for the vutrisiran market size predicts significant growth in the coming years, with projections estimating a value of $1.08 billion by 2029, reflecting a compound annual growth rate (CAGR) of 12.4%. This forecasted growth is likely due to enhanced availability of healthcare services, an upsurge in chronic disease incidence, increased spending in research and development, a heightened emphasis on personalized medicine, and growing disease awareness. The forecast period is also anticipated to see trends such as advancements in combination therapy, shift towards targeted therapy, further progress in personalized medicine, enhancement in digital health technology, and innovative developments in biotechnology.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21320&type=smp

What Are the Core Market Drivers Propelling Growth in the Vutrisiran Industry?

The surge in funding for research and development is anticipated to boost the growth trajectory of the vutrisiran market. This specific type of investment is typically aimed at the innovation and enhancement of products, services or processes by means of organized exploration and testing. The upswing in research and development funding can be attributed to factors such as government programs and contributions, the expanding requirements of healthcare and pharmaceutical sectors, as well as concerns about sustainability and the environment. The funds allocated for research and development enable drug companies to undertake clinical studies, which highlight the long-term advantages and safety of the drug, thereby leading to wider regulatory permissions. Furthermore, breakthroughs in RNA interference (RNAi) technology enhances the exactness of the drug, mitigating adverse reactions and boosting patient acceptance. For example, as per data from Eurostat – the statistical office of the European Union based in Luxembourg, in December 2023, it was found that the funding for research and development in the European Union escalated to €352 billion ($384.42 billion) in 2022. This reflected a 6.34% increase from the €331 billion ($361.48 billion) allocated the prior year. Thus, the augmented investment in research and development is a key driving force behind the growth of the vutrisiran market.

How Is the Vutrisiran Market Segmented?

The vutrisiran market covered in this report is segmented –

1) By Drug Class: Antisense Oligonucleotide, Nucleic Acids, Nucleotide, Nucleoside, Other Drug Classes

2) By Route Of Administration: Oral, Injectable, Subcutaneous

3) By Patient Demographics: Pediatric, Adult, Geriatric

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Antisense Oligonucleotide: Single-Stranded Antisense Oligonucleotides, Double-Stranded Antisense Oligonucleotides

2) By Nucleic Acids: DNA-based Nucleic Acids, RNA-based Nucleic Acids

3) By Nucleotide: Purine Nucleotides, Pyrimidine Nucleotides

4) By Nucleoside: Purine Nucleosides, Pyrimidine Nucleosides

5) By Other Drug Classes: Peptide-Based Drugs, Protein Therapeutics

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21320&type=smp

Which Regions Are Driving the Next Phase of the Vutrisiran Market Growth?

North America was the largest region in the vutrisiran market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vutrisiran market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Vutrisiran Industry?

The primary trend in the vutrisiran market revolves around the cultivation of novel therapeutic approaches, such as subcutaneous RNAi therapeutics, to introduce more user-friendly and less frequent dosing alternatives for hereditary transthyretin-mediated (hATTR) amyloidosis management. Subcutaneous RNAi therapeutics are treatments that utilize RNA interference technology and are injected under the skin for sustained release. The objective of this technique is to maintain consistent drug levels over an extended period, enhancing patient comfort and consistency in managing polyneuropathy linked with hereditary transthyretin-mediated (hATTR) amyloidosis. For example, in June 2022, Alnylam Pharmaceuticals, a US-based biopharmaceutical enterprise, declared FDA approval for vutrisiran (AMVUTTRA), a treatment for polyneuropathy in adults associated with hATTR amyloidosis. It brings considerable relief to neuropathy symptoms and impedes disease escalation. The HELIOS-A Phase 3 trial revealed disease reversal or slowdown in over half the patients. AMVUTTRA has showcased an encouraging safety profile, with no drug-related cessation or fatalities, and a dose schedule that may enhance patient adherence.

View the full report here:

https://www.thebusinessresearchcompany.com/report/vutrisiran-global-market-report

How Is the Vutrisiran Market Defined and What Are Its Core Parameters?

Vutrisiran is a small interfering RNA (siRNA) therapy for hereditary transthyretin-mediated (hATTR) amyloidosis. It silences the transthyretin (TTR) gene, reducing abnormal TTR protein deposits that cause polyneuropathy and organ damage. Vutrisiran helps slow disease progression and improve neurological function, mobility, and quality of life with a longer dosing interval.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21320

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model